Digging into Dig[oxin]

Dr. Robert DiDomenico and CardioScripts co-host, Dr. Tracy Macaulay, discuss the RATE AF trial and all things digoxin: its past role, therapeutic levels, and current and future state! 0:00-0:32 Intro 0:28-1:02: Welcome back and Introduction of Dr. DiDomenico 1:03-4:33: Overview of the RATE-AF trial as presented at ESC 2020 and based on published trial rationale.Continue reading “Digging into Dig[oxin]”

HOCM POCM and Magical Mavacamten

Dr. Ashley Schenk discusses mavacamten and obstructive hypertrophic cardiomyopathy. 0:00-0:28: Intro 0:29-1:09: Introduction of Dr. Ashley Schenk 1:10-5:55: Trial overview 5:56-8:36: Overview of obstructive hypertrophic cardiomyopathy 8:37-10:23: Pharmacological therapy used in patients with obstructive hypertrophic cardiomyopathy and why mavacamten is different 10:24-11:14: Initial thoughts about the trial 11:15-13:30: Beta-blocker subgroup analysis and disopyramide exclusion 13:31-15:05:Continue reading “HOCM POCM and Magical Mavacamten”

CardioScripts Classic – Antiplatelets in ACS [Part 2]

0:00-0:58: Intro 0:59-4:47: 1-year after ISAR-REACT 5, does prasugrel reign supreme? 4:48-7:32: Dr. Dunn and Dr. Macaulay dive into the confusing world of DAPT duration.  Who should get shorter and who get longer, based on DAPT trial, PEGASUS, TWILIGHT, TICO, and more.  7:33-10:46: When de-escalation is indicated, should it be aspirin or P2Y12 inhibitor thatContinue reading “CardioScripts Classic – Antiplatelets in ACS [Part 2]”

CardioScripts Classic – Antiplatelets in ACS [Part 1]

0:00-0:27: Intro 0:28-1:04: Welcome back and Introduction of Dr. Dunn 1:05-6:18 Foundation of antiplatelet therapy with aspirin in ISIS-2 trail and VA Cooperative Study.  What is up with that subgroup analysis? 6:19-10:39: Percutaneous intervention joins conversation develops and STARS trial compares Aspirin alone, aspirin + warfarin, aspirin + ticagrelor in the setting of stenting. 10:40-13:57:Continue reading “CardioScripts Classic – Antiplatelets in ACS [Part 1]”

DOACs and LV Thrombus Management

0:00-0:42: Intro 0:43-1:53: Introduction of Dr. Kazuhiko Kido 1:54-6:02: Trial Overview 6:03-9:09: Previous Data for LV Thrombus Management 9:10-10:10: Overall Thoughts 10:11-12:44: Trial Limitations 12:45-15:01: Background Medications and LV Thrombus secondary to ischemic cardiomyopathy vs. non-ischemic cardiomyopathy 15:02-19:08: LV thrombus anticoagulation management in patients 19:09-19:54: Closing References: Robinson AA, Trankle CR, Eubanks G, et al.Continue reading “DOACs and LV Thrombus Management”

CardioScripts Classics – Vasodilators in HFrEF [Part 2]

0:00-0:43: Intro 0:44-1:04: Welcome back of Dr. Robert Page and Recap of Part 1 1:05-3:09: Discussion of ARB trials in HFrEF from highlighting ELITE I and II 3:10-7:42: What we learned from Val-HeFT and CHARM-ADDED 7:43-11:13: Angioedema approach, lessons from CHARM-ALTERNATIVE and HTN trials 11:14-14:10: PARADIGM-HF a shift in vasodilator therapy for HFrEF 14:11-16:48: DoseContinue reading “CardioScripts Classics – Vasodilators in HFrEF [Part 2]”

CardioScipts Classic – Vasodilators in HFrEF [Part 1]

Dr. Robert Page and CardioScripts co-host, Dr. Tracy Macaulay, take a deep dive into classic literature pertaining to use of vasodilators in HFrEF. 0:00-0:47: Intro 0:41-1:23: Introduction of Dr. Robert Page 1:23-2:16: Intro of the Classic Episode Format 2:17-6:48: Foundation of HFrEF pharmacotherapy prior to 1986 and discussion of the V-HeFT I trial 6:48-9:12: CONSENSUSContinue reading “CardioScipts Classic – Vasodilators in HFrEF [Part 1]”

To be[ta-block], or not to be[ta-block]? How long is long the question.

Dr. Kristin Watson discusses the use of beta-blockers post-MI in patients without heart failure. 0:00-0:40: Intro 0:41-1:18: Introduction of Dr. Kristin Watson 1:19-6:40: Trial overview 6:41-10:46: Background of beta-blocker use post-MI 10:47-12:36: Kristin’s overall thoughts 12:37-14:49: Types of beta-blockers used 14:50-16:06: Final thoughts 16:07-16:49: Closing References: Kim J, Kang D, Park H, et al. Long-termContinue reading “To be[ta-block], or not to be[ta-block]? How long is long the question.”

VOYAGER PAD: Live Long and Rivaroxaban

Dr. Jessica Carey discusses the VOYAGER PAD trial and antithrombotic management in PAD patients post-revascularization. 0:00-0:40: Intro 0:41-1:46: Introduction of Dr. Jessica Carey 1:47-5:52: VOYAGER PAD Overview 5:53-9:10: Previous management of PAD 9:11-11:18: PAD Interventions 11:19-13:49: Overall thoughts about VOYAGER PAD 13:50-15:19: Antithrombotic management of PAD 15:19-16:01: Closing References: VOYAGER PAD: Bonaca MP, Bauersachs RM,Continue reading “VOYAGER PAD: Live Long and Rivaroxaban”

The Caravaggio Trial: Painting DOACs into the Picture

Guest Dr. Paul Dobesh discusses the Caravaggio trial and DOAC use for VTE management in patients with cancer. 0:00-0:40: Intro0:41-1:35: Introduction of Dr. Paul Dobesh1:36-4:02: Caravaggio trial overview 4:03-7:08: Background of VTE antithrombotic management in cancer 7:09-9:09: Overall thoughts and where apixaban fits9:10-10:42: ADAM-VTE Trial10:43-13:36: Bleeding13:37-14:37: PROBE trial design14:38-15:47: Approach the VTE antithrombotic management inContinue reading “The Caravaggio Trial: Painting DOACs into the Picture”